KRAS mutations and mutations in the RAS-MAPK pathway show heterogeneous incidence among mature B cell neoplasms without apparent association with specific B cell differentiation stages or with specific signaling dependencies (e.g., BCR signaling or microenvironment). This evidence concerns the gene KRAS and B-cell neoplasm.